Literature DB >> 17442342

Analyzing the "degree of humanness" of antibody sequences.

K R Abhinandan1, Andrew C R Martin.   

Abstract

Genetically engineered mouse antibodies are now commonly in clinical use. However, their development is limited because the human immune system tends to regard them as foreign and this triggers an immune response. The solution is to make engineered antibodies appear more human. Here, we propose a method to assess the "degree of humanness" of antibody sequences providing a tool that may contribute to predictions of antigenicity. We analyzed sequences of antibodies belonging to various chains/classes in human and mouse. Our analysis of metrics based on percentage sequence identity between antibody sequences shows distinct differences between human and mouse sequences. Based on mean sequence identity and standard deviation, we calculated Z-scores for data sets of antibody sequences extracted from the Kabat database. We applied the analysis to a set of humanized and chimeric antibodies and to human germline sequences. We conclude that this approach may aid in the selection of more suitable mouse variable domains for antibody engineering to render them more human but in general, we find that typicality of a sequence compared with the expressed human repertoire is not well correlated with antigenicity. We have provided a Web server allowing humanness to be assigned for a sequence.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442342     DOI: 10.1016/j.jmb.2007.02.100

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  38 in total

1.  A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering.

Authors:  Philippe Thullier; Siham Chahboun; Thibaut Pelat
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

2.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

3.  Antibody humanization by structure-based computational protein design.

Authors:  Yoonjoo Choi; Casey Hua; Charles L Sentman; Margaret E Ackerman; Chris Bailey-Kellogg
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

4.  Understanding differences between synthetic and natural antibodies can help improve antibody engineering.

Authors:  Anat Burkovitz; Yanay Ofran
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

5.  Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.

Authors:  Derek M Mason; Simon Friedensohn; Cédric R Weber; Christian Jordi; Bastian Wagner; Simon M Meng; Roy A Ehling; Lucia Bonati; Jan Dahinden; Pablo Gainza; Bruno E Correia; Sai T Reddy
Journal:  Nat Biomed Eng       Date:  2021-04-15       Impact factor: 25.671

6.  Machine Learning Attempts for Predicting Human Subcutaneous Bioavailability of Monoclonal Antibodies.

Authors:  Hao Lou; Michael J Hageman
Journal:  Pharm Res       Date:  2021-03-12       Impact factor: 4.200

7.  Beyond CDR-grafting: Structure-guided humanization of framework and CDR regions of an anti-myostatin antibody.

Authors:  James R Apgar; Michelle Mader; Rita Agostinelli; Susan Benard; Peter Bialek; Mark Johnson; Yijie Gao; Mark Krebs; Jane Owens; Kevin Parris; Michael St Andre; Kris Svenson; Carl Morris; Lioudmila Tchistiakova
Journal:  MAbs       Date:  2016-09-13       Impact factor: 5.857

Review 8.  How repertoire data are changing antibody science.

Authors:  Claire Marks; Charlotte M Deane
Journal:  J Biol Chem       Date:  2020-05-14       Impact factor: 5.157

9.  Paper Title "Hu7CG2: A Novel Humanized Anti-Epidermal Growth Factor Receptor (EGFR) Biparatopic Nanobody".

Authors:  Jafar Sharifi; Mohammad Reza Khirehgesh; Bahman Akbari; Bijan Soleymani; Kamran Mansouri
Journal:  Mol Biotechnol       Date:  2021-03-26       Impact factor: 2.695

10.  Blind prediction performance of RosettaAntibody 3.0: grafting, relaxation, kinematic loop modeling, and full CDR optimization.

Authors:  Brian D Weitzner; Daisuke Kuroda; Nicholas Marze; Jianqing Xu; Jeffrey J Gray
Journal:  Proteins       Date:  2014-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.